RPRX
Royalty Pharma plc · Healthcare · Market cap $34.6B
Insiders sold $13.0M net in the last 90 days ·3 sellers, 0 buyers· 5 of 5 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 5, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$92.8M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Oct 5, 2026
Urist Marshall
Royalty Pharma plc (RPRX) has 67 SEC Form 4 filings (105 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Oct 5, 2026.
Inside the rolling window, 5 insiders at Royalty Pharma plc reported no open-market purchases and 41 open-market sales totaling $92.8M. The most active filer is EVP, Research & Investments Urist Marshall with 16 filings. Insiders have net sold $36.3M over the trailing 6 months. The most recent open-market filing is a sale of 4,126 shares by EVP, Research & Investments Urist Marshall, dated Oct 5, 2026, worth $236K.
- Industry:Medical - Pharmaceuticals
- CEO:Pablo Legorreta
- Employees:100
- HQ:New York, NY, US
- IPO:2020-06-16
| Source | |||||||
|---|---|---|---|---|---|---|---|
| EVP, Research & Investments | Sale | 4,126 | $236K | Oct 5 | +9.7% | SEC ↗ | |
Urist MarshallFirst in 3 months | EVP, Research & Investments | Sale | 4,126 | $239K | Sep 30 | +6.5% | SEC ↗ |
| EVP & Chairman, Partnering | Sale | 100,000 | $5.9M | Sep 24 | +6.6% | SEC ↗ | |
| EVP & Chairman, Partnering | Sale | 100,000 | $6.0M | Aug 19 | +0.7% | SEC ↗ | |
| EVP & CFO | Sale | 11,002 | $646K | Aug 17 | +4.5% | SEC ↗ | |
| EVP & Chairman, Partnering | Sale | 130,000 | $7.3M | Jul 2 | +7.6% | SEC ↗ | |
| EVP, Research & Investments | Sale | 9,099 | $508K | Jul 2 | — | SEC ↗ | |
Hite ChristopherFirst filing | EVP & Chairman, Partnering | Sale | 150,000 | $8.2M | Jun 25 | — | SEC ↗ |
| EVP, Research & Investments | Sale | 9,098 | $502K | Jun 25 | — | SEC ↗ | |
| EVP & CFO | Sale | 64,399 | $3.5M | May 28 | — | SEC ↗ | |
| EVP, Research & Investments | Sale | 13,684 | $722K | May 22 | — | SEC ↗ | |
Urist MarshallFirst in 3 months | EVP, Research & Investments | Sale | 13,684 | $726K | May 15 | — | SEC ↗ |
Norden GregoryFirst filing | Director | Sale | 3,045 | $161K | May 15 | — | SEC ↗ |
| EVP & CFO | Sale | 34,791 | $1.7M | Apr 30 | — | SEC ↗ | |
| EVP & CFO | Sale | 34,791 | $1.7M | Apr 2 | — | SEC ↗ | |
| EVP & CFO | Sale | 34,791 | $1.6M | Mar 25 | — | SEC ↗ | |
| EVP & CFO | Sale | 34,791 | $1.6M | Mar 4 | — | SEC ↗ | |
| EVP & CFO | Sale | 34,791 | $1.6M | Feb 25 | — | SEC ↗ | |
| EVP & CFO | Sale | 108,424 | $4.6M | Feb 4 | — | SEC ↗ | |
| EVP & CFO | Sale | 114,954 | $4.9M | Feb 4 | — | SEC ↗ | |
| EVP & CFO | Sale | 20,163 | $873K | Feb 4 | — | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $822K | Feb 2 | — | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $805K | Jan 26 | — | SEC ↗ | |
| EVP & CFO | Sale | 69,582 | $2.7M | Jan 23 | — | SEC ↗ | |
| EVP, Research & Investments | Sale | 20,000 | $790K | Jan 20 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does RPRX have?
Royalty Pharma plc (RPRX) has 67 SEC Form 4 filings (105 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Oct 5, 2026.
When was the most recent SEC Form 4 filing for RPRX?
The most recent Form 4 filing for RPRX on Tracefour is dated Oct 5, 2026.
Who is the most active insider at RPRX?
The most active SEC Form 4 filer at RPRX in the rolling window is EVP, Research & Investments Urist Marshall, with 16 filings.
What is the net insider flow at RPRX over the last 6 months?
Over the trailing 180 days, insiders at RPRX have net sold $36.3M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at RPRX in the current window?
Inside the rolling window, insiders at RPRX bought $0 and sold $92.8M based on SEC Form 4 filings.
Can I get alerts for RPRX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Royalty Pharma plc (RPRX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Royalty Pharma plc is in the Healthcare sector.